Antibiotic lung penetration study launches in china
NCT ID NCT07124468
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial in 16 healthy adults in China measures how much of the intravenous antibiotic Meropenem-Pralubactam gets into lung fluids and cells. Researchers aim to find the drug's concentration in plasma, epithelial lining fluid, and alveolar macrophages after four doses. The study does not treat any infection but provides key data for future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Meropenem-Pralubactam (an antibiotic combination given intravenously)
What this could lead to
If successful, this study could help doctors understand the right dose of this antibiotic to treat lung infections.
What could go wrong
This is a very early, small study in healthy people, not patients. It only measures drug levels, not whether the drug works against infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••